Interaction of combinations of drugs, chemosensitisers, and peptides with the P-glycoprotein multidrug transporter

被引:32
|
作者
DiDiodato, G [1 ]
Sharom, FJ [1 ]
机构
[1] UNIV GUELPH,GUELPH WATERLOO CTR GRAD WORK CHEM,DEPT CHEM & BIOCHEM,GUELPH,ON N1G 2W1,CANADA
关键词
multidrug resistance; plasma membrane vesicles; drug transport; median effect analysis; synergism; antagonism;
D O I
10.1016/S0006-2952(97)00007-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-Glycoprotein functions as an ATP-driven efflux pump for hydrophobic natural products andeptides, and gives rise to resistance to multiple chemotherapeutic drugs. The inhibition of colchicine transport via P-glycoprotein by various compounds was determined in a plasma membrane vesicle model system. A chemotherapeutic drug (vinblastine) and several chemosensitizers (verapamil, reserpine, cyclosporin A) and hydrophobic peptides (N acetyl-leucyl-leucyl-methioninal, leupeptin, pepstatin A, valinomycin) were exam ined, both as individual species and as combinations of compounds. The median effect analysis was used to determine the concentration of each combination required to produce a median effect, D-m, as well as the sigmoidicity of the concentration-effect plot, m. The combination of cyclosporin A and verapamil was the only one established to be mutually nonexclusive, whereas several mutually exclusive pairs of compounds were identified. The combination index, CI, was calculated for several combinations of drugs, chemosensitizers, and peptides, and used to ascertain whether effects were synergistic, antagonistic, or additive. Some combinations (vinblastine/verapamil; verapamil/valinomycin) showed antagonism over the entire concentration range. Other combinations (valinomycinl/N acetyl-leucyl-leucyl-methioninal; cyclosporin A/verapamil) displayed both synergism and antagonism over different regions of the CI plot. Many combinations of compounds displayed additive interactions over most of the CI plot. The median effect analysis may be helpful in identifying potentially useful additive or synergistic combinations of compounds for reversal of Pgp-mediated drug resistance. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:1789 / 1797
页数:9
相关论文
共 50 条
  • [1] INTERACTION OF THE P-GLYCOPROTEIN MULTIDRUG TRANSPORTER WITH PEPTIDES AND IONOPHORES
    SHAROM, FJ
    DIDIODATO, G
    YU, XH
    ASHBOURNE, KJD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (17) : 10334 - 10341
  • [2] Interaction of the P-Glycoprotein Multidrug Transporter with Sterols
    Clay, Adam T.
    Lu, Peihua
    Sharom, Frances J.
    BIOCHEMISTRY, 2015, 54 (43) : 6586 - 6597
  • [3] INTERACTION OF FORSKOLIN WITH THE P-GLYCOPROTEIN MULTIDRUG TRANSPORTER
    MORRIS, DI
    SPEICHER, LA
    RUOHO, AE
    TEW, KD
    SEAMON, KB
    BIOCHEMISTRY, 1991, 30 (34) : 8371 - 8379
  • [4] Interaction of the P-glycoprotein multidrug transporter with cholesterol
    Eckford, PDW
    Sharom, FJ
    BIOPHYSICAL JOURNAL, 2005, 88 (01) : 186A - 187A
  • [5] The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs
    Stepien, Karolina M.
    Tomaszewski, Michal
    Tomaszewska, Joanna
    Czuczwar, Stanislaw J.
    PHARMACOLOGICAL REPORTS, 2012, 64 (05) : 1011 - 1019
  • [6] The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs
    Stȩpień K.M.
    Tomaszewski M.
    Tomaszewska J.
    Czuczwar S.J.
    Pharmacological Reports, 2012, 64 (5) : 1011 - 1019
  • [7] The P-glycoprotein multidrug transporter
    Sharom, Frances J.
    ESSAYS IN BIOCHEMISTRY: ABC TRANSPORTERS, 2011, 50 : 161 - 178
  • [8] The P-glycoprotein multidrug transporter
    Fardel, O
    Lecureur, V
    Guillouzo, A
    GENERAL PHARMACOLOGY, 1996, 27 (08): : 1283 - 1291
  • [9] Kinetics of the P-glycoprotein, the multidrug transporter
    Stein, WD
    EXPERIMENTAL PHYSIOLOGY, 1998, 83 (02) : 221 - 232
  • [10] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein
    Wang, Jun-Sheng
    Zhu, Hao-Jie
    Markowitz, John S.
    Donovan, Jennifer L.
    DeVane, C. Lindsay
    PSYCHOPHARMACOLOGY, 2006, 187 (04) : 415 - 423